Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:3/24/2019
Start Date:May 10, 2018
End Date:December 2022
Contact:Lori A. Ladd
Email:patientinfo@novocure.com
Phone:+1 603 389 2158

Use our guide to learn which trials are right for you!

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma

Brief Summary:

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy
and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and
nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The
device is an experimental, portable, battery operated device for chronic administration of
alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by
means of surface, insulated electrode arrays.

PAST PRE-CLINICAL AND CLINICAL EXPERIENCE:

The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in
vitro and in vivo pancreatic adenocarcinoma pre-clinical models both as a single modality
treatment and in combination with chemotherapies. TTFields have been demonstrated to act
synergistically with taxanes and have been shown to be additive when combined with other
chemotherapies including gemcitabine. In addition, TTFields have shown to inhibit metastatic
spread of malignant melanoma in in vivo experiment.

In a pilot study, 40 patients with locally advanced or metastatic pancreatic adenocarcinoma
received gemcitabine together with TTFields (150 kHz) or gemcitabine and nab-paclitaxel
together with TTFields (150 kHz) applied to the abdomen until disease progression. The
combination was well tolerated and the only device-related adverse event was contact
dermatitis.

In addition, a phase III trial of Optune® (200 kHz) as monotherapy compared to active
chemotherapy in recurrent glioblastoma patients showed TTFields to be equivalent to active
chemotherapy in extending survival, associated with minimal toxicity, good quality of life,
and activity within the brain (14% response rate) (Stupp R., et al., EJC 2012). Finally, a
phase III trial of Optune® combined with maintenance temozolomide compared to maintenance
temozolomide alone has shown that combined therapy led to a significant improvement in both
progression free survival and overall survival in patients with newly diagnosed glioblastoma
without the addition of high grade toxicity and without decline in quality of life (Stupp R.,
et al., JAMA 2017).

DESCRIPTION OF THE TRIAL:

All patients included in this trial are patients with locally advanced pancreatic
adenocarcinoma. In addition, all patients must meet all eligibility criteria.

Eligible patients will be randomly assigned to one of two groups:

1. Patients receive gemcitabine and nab-paclitaxel in combination with TTFields using the
NovoTTF-100L(P) System.

2. Patients receive gemcitabine and nab-paclitaxel without TTFields.

Patients will be randomized at a 1:1 ratio. Baseline tests will be performed in patients
enrolled in both arms. If assigned to the NovoTTF-100L(P) group, the patients will be treated
continuously with the device until progression in the abdomen. On both arms, patients who
have progression outside the abdomen will switch to a second line treatment according to
local practice.

SCIENTIFIC BACKGROUND:

Electric fields exert forces on electric charges similar to the way a magnet exerts forces on
metallic particles within a magnetic field. These forces cause movement and rotation of
electrically charged biological building blocks, much like the alignment of metallic
particles seen along the lines of force radiating outwards from a magnet.

Electric fields can also cause muscles to twitch and if strong enough may heat tissues.
TTFields are alternating electric fields of low intensity. This means that they change their
direction repetitively many times a second. Since they change direction very rapidly (150
thousand times a second), they do not cause muscles to twitch, nor do they have any effects
on other electrically activated tissues in the body (brain, nerves and heart). Since the
intensities of TTFields in the body are very low, they do not cause heating.

The breakthrough finding made by Novocure was that finely tuned alternating fields of very
low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in
the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are
multiplying, TTFields cause electrically-charged cellular components of these cells to change
their location within the dividing cell, disrupting their normal function and ultimately
leading to cell death. In addition, cancer cells also contain miniature building blocks which
act as tiny motors in moving essential parts of the cells from place to place. TTFields
interfere with the normal orientation of these tiny motors related to other cellular
components since they are electrically-charged as well. As a result of these two effects,
tumor cell division is slowed, results in cellular death or reverses after continuous
exposure to TTFields.

Other cells in the body (normal healthy tissues) are affected much less than cancer cells
since they multiply at a much slower rate if at all. In addition TTFields can be directed to
a certain part of the body, leaving sensitive areas out of their reach. Finally, the
frequency of TTFields applied to each type of cancer is specific and may not damage normally
dividing cells in healthy tissues.

In conclusion, TTFields hold the promise of serving as a brand new treatment for pancreatic
adenocarcinoma with very few side effects.

Inclusion Criteria:

1. 18 years of age and older

2. Life expectancy of ≥ 3 months

3. Histological/cytological diagnosis of de novo adenocarcinoma of the pancreas

4. Unresectable, locally advanced stage disease according to the following criteria:

- Head/uncinate process:

1. Solid tumor contact with SMA>180°

2. Solid tumor contact with the CA>180°

3. Solid tumor contact with the first jejunal SMA branch

4. Unreconstructible SMV/PV due to tumor involvement or occlusion (can be d/t
tumor or bland thrombus)

5. Contact with most proximal draining jejunal branch into SMV

- Body and tail

1. Solid tumor contact of >180° with the SMA or CA

2. Solid tumor contact with the CA and aortic involvement

3. Unreconstructible SMV/PV due to tumor involvement or occlusion (can be d/t
tumor or bland thrombus)

- No distant metastasis, including non-regional lymph node metastasis

- No borderline resectable (per Al-Hawary MM, et al., Radiology 201414)

5. ECOG score 0-2

6. Amenable and assigned by the investigator to receive therapy with gemcitabine and
nab-paclitaxel

7. Able to operate the NovoTTF-100L(P) System independently or with the help of a
caregiver

8. Signed informed consent form for the study protocol

Exclusion Criteria:

1. Prior palliative treatment (e.g. surgery, radiation) to the tumor

2. Cancer requiring anti-tumor treatment within the 5 years before inclusion, excluding
treated stage I prostate cancer, in situ cervical or uterus cancer, in situ breast
cancer and non-melanomatous skin cancer.

3. Serious co-morbidities:

1. Clinically significant (as determined by the investigator) hematological, hepatic
and renal dysfunction, defined as: Neutrophil count < 1.5 x 10^9/L and platelet
count < 100 x 10^9/L; bilirubin > 1.5 x Upper Limit of Normal (ULN); AST and/or
ALT > 2.5 x ULN; and serum creatinine > 1.5 x ULN.

2. History of significant cardiovascular disease unless the disease is well
controlled. Significant cardiac disease includes second/third degree heart block;
significant ischemic heart disease; poorly controlled hypertension; congestive
heart failure of the New York Heart Association (NYHA) Class II or worse (slight
limitation of physical activity; comfortable at rest, but ordinary activity
results in fatigue, palpitation or dyspnea).

3. History of arrhythmia that is symptomatic or requires treatment. Patients with
atrial fibrillation or flutter controlled by medication are not excluded from
participation in the trial.

4. History of cerebrovascular accident (CVA) within 6 months prior to randomization
or that is not stable.

5. Active infection or serious underlying medical condition that would impair the
ability of the patient to receive protocol therapy.

6. History of any psychiatric condition that might impair patient's ability to
understand or comply with the requirements of the study or to provide consent.

4. Concurrent anti-tumor therapy beyond gemcitabine and nab-paclitaxel

5. Implantable electronic medical devices in the torso, such as pacemakers

6. Known severe hypersensitivities to medical adhesives or hydrogel, or to one of the
chemotherapies used in this trial.

7. Pregnancy or breast-feeding (female patients with reproductive potential and their
partners must accept to use effective contraception throughout the entire study period
and for 3 months after the end of treatment). All patients who are capable of becoming
pregnant must take a pregnancy test which is negative within 72 hours before beginning
treatment. The definition of effective contraception is left up to the decision of the
investigator.

8. Unable to follow the protocol for medical, psychological, familial, geographic or
other reasons.

9. Admitted to an institution by administrative or court order.
We found this trial at
43
sites
Seattle, Washington 98101
(888) 862-2737
Principal Investigator: Vincent Picozzi, MD
Phone: 206-287-5671
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Benjamin Schlechter, MD
Phone: 617-975-7405
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Emil Lou, MD
Phone: 612-626-0343
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Andrew Coveler, MD
Phone: 206-606-6405
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Anaheim, California 92801
Principal Investigator: Ajit Maniam
Phone: 714-999-1465
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Arlington Heights, Illinois 60005
Principal Investigator: Richard Siegel, MD
Phone: 281-863-6662
?
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Atlanta, Georgia 30318
Principal Investigator: Trevor Feinstein, MD
Phone: 678-298-3238
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Beaumont, Texas 77702
Principal Investigator: Scott A. McKenney, MD
Phone: 281-863-6662
?
mi
from
Beaumont, TX
Click here to add this to my saved trials
Bedford, Texas 76022
Principal Investigator: Henrik Illum, MD
Phone: 281-863-6662
?
mi
from
Bedford, TX
Click here to add this to my saved trials
Bridgeport, Connecticut 06460
Principal Investigator: Nicholas Blondin, MD
?
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Chattanooga, Tennessee 37403
Principal Investigator: Sumana Nagireddy, MD
Phone: 423-778-6931
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Columbia, Maryland 21044
Principal Investigator: Mohit Narang, MD
Phone: 281-863-6662
?
mi
from
Columbia, MD
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Carlos R. Becerra, MD
Phone: 281-863-6662
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Philip A. Philip, MD,PhD,FRCP
Phone: +1 800-KARMANOS (800-527-6266)
?
mi
from
Detroit, MI
Click here to add this to my saved trials
El Paso, Texas 79915
Principal Investigator: Panagiotis Valilis, MD
Phone: 281-863-6662
?
mi
from
El Paso, TX
Click here to add this to my saved trials
Eugene, Oregon 97401
Principal Investigator: Marc Uemura, MD
Phone: 281-863-6662
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Fairway, Kansas 66205
Principal Investigator: Anup Kasi, MD
Phone: 913-588-6939
?
mi
from
Fairway, KS
Click here to add this to my saved trials
Fort Myers, Florida 33916
Principal Investigator: James Reeves, MD
Phone: 239-274-9930
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Fountain Hill, Pennsylvania 18015
Principal Investigator: Anna Niewiarowska, MD
Phone: 610-866-0113
?
mi
from
Fountain Hill, PA
Click here to add this to my saved trials
Gilbert, Arizona 85234
Principal Investigator: Tomislav Dragovich, MD, PhD
Phone: 480-256-5164
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Sreenivasa Chandana, MD
Phone: 616-954-5550 ext. 2041
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Kansas City, Missouri 64132
Principal Investigator: Jaswinder Singh, MD
Phone: 844-482-4812
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lake Success, New York 11042
Principal Investigator: Francis Arena, MD FACP
Phone: 516-466-6611 x 135
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
9280 W. Sunset Road Suite 100
Las Vegas, Nevada 89148
702.952.1251
Principal Investigator: Fadi Braiteh, MD
Phone: 702-862-1110
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: John T. Hamm, MD
Phone: 502-629-3449
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Maywood, Illinois 60153
Principal Investigator: William Small Jr., MD
?
mi
from
Maywood, IL
Click here to add this to my saved trials
Miami Beach, Florida 33140
Principal Investigator: Mike Cusnir, MD
Phone: 305-674-2625 ext. 50714
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
1 Medical Center Drive
Morgantown, West Virginia 26506
Principal Investigator: Joanna Kolodney, MD
Phone: 304-293-2633
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Johanna Bendell, MD
Phone: 615-329-7359
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1514 Jefferson Hwy.
New Orleans, Louisiana 70121
504-842-3000
Principal Investigator: Marc Matrana, MD
Phone: 504-703-2654
Ochsner Medical Center Ochsner Medical Center is located near uptown New Orleans and includes acute...
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Principal Investigator: Timothy Huyck, MD
Phone: 402-354-5831
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Plantation, Florida 33322
Principal Investigator: Jason Tache, MD
Phone: 561-447-0614
?
mi
from
Plantation, FL
Click here to add this to my saved trials
1155 Mill Street
Reno, Nevada 89502
Principal Investigator: Garrett Green, MD
Phone: 775-982-5050
?
mi
from
Reno, NV
Click here to add this to my saved trials
Roanoke, Virginia 24014
Principal Investigator: Mark Kochenderfer, MD
Phone: 281-863-6662
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
4001 J Street
Sacramento, California 95186
Principal Investigator: Samer Shihabi, MD
Phone: (916) 863-8731
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Petersburg, Florida 33705
Principal Investigator: Sunil G. Gandhi, MD
Phone: (727)216-1143 Ext. 1-3085
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Salzburg,
Principal Investigator: Richard Greil, MD
Phone: +43 (0) 5 7255 - 25823
?
mi
from
Salzburg,
Click here to add this to my saved trials
Tampa, Florida 33613
Principal Investigator: Alexander Rosemurgy, MD
Phone: 813-615-7068
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1414 SW 8th Ave
Topeka, Kansas 66606
(785) 354-5300
Principal Investigator: David E. Einspahr, MD
Phone: 785-270-4964
Cotton-O'Neil Cancer Center The state-of-the-art Stormont-Vail Cancer Center is one of the specialty medical centers...
?
mi
from
Topeka, KS
Click here to add this to my saved trials
Tucson, Arizona 85724
Principal Investigator: Hani M. Babiker, MD
Phone: 520-626-9083
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tucson, Arizona 85711
Principal Investigator: Sudhir Manda, MD
Phone: 281-863-6662
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tyler, Texas 75702
Principal Investigator: Donald Richards, MD
Phone: 281-863-6662
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
Principal Investigator: Judith Sears, MD
Phone: 336-718-8335
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials